Market accessOfficial
Estonia's human medicines market grows 11.7% in third quarter of 2026
🇪🇪 Ravimiamet · Mon 16 Nov 2026
Ravimiamet reports human medicines turnover of €154 million for Q3 2026, while the veterinary market rose 1.3% to €5.1 million year on year.
Estonia's human medicines market grew by 11.7% in the third quarter of 2026 compared with the same period of 2025, reaching €154 million, according to figures from the State Agency of Medicines (Ravimiamet). The veterinary medicines market grew 1.3%, to €5.1 million.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: Ravimiamet ↗
Article written by VigiEye from the official source (Ravimiamet). AI-assisted; check the source before acting.
More Market access
All →
China adds Ascentage's lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation
Ascentage Pharma Group International (AAPG) · Mon 16 Nov 2026
INFARMED updates Portugal's reference price groups for fourth quarter of 2026
🇵🇹 INFARMED · Mon 16 Nov 2026
AIFA updates Italy's Transparency Lists of generics and reference prices as of 16 November
🇮🇹 AIFA · Mon 16 Nov 2026
ANSM issues new accreditation rules for external quality control bodies, repealing 2019 order
🇫🇷 ANSM · Mon 16 Nov 2026
AIFA publishes updated transparency lists with generic reference prices as of 16 November
🇮🇹 AIFA · Mon 16 Nov 2026
MSD to end Emend (aprepitant) marketing in EU/EEA; Italy's 125 mg + 80 mg capsules go from 30 November
🇮🇹 AIFA · Mon 16 Nov 2026